Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?

Biotech giant Gilead Sciences, Inc.’s (GILD) shares have risen 44.2% in the past six months compared with the industry’s growth of 1.1%. The stock has also outperformed the sector and the S&P 500. It has grown steadily in the past six months.Earlier this month, Gilead reported better-than-expected third-quarter results and raised its annual earnings guidance yet again. Revenues increased 7% from the year-ago quarter’s level due to high HIV and Veklury sales.Approval of new drugs and encouraging pipeline pro ...